BETA
Home MEPs Dossiers Committees Subjects Blog About Dumps
download json


2014/0183(NLE) Subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead LIBE JIMÉNEZ-BECERRIL BARRIO Teresa (icon: PPE PPE)
Committee Opinion ENVI
Lead committee dossier:
Legal Basis:
Treaty on the European Union (after Amsterdam) M 039-p1

Events

2015/10/20
   Final act published in Official Journal
Details

PURPOSE: to apply control measures to new psychoactive substances.

NON-LEGISLATIVE ACT: Council Implementing Decision (EU) 2015/1875 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures.

CONTENT: the Council adopted an implementing decision on subjecting the new psychoactive substances to control measures across the European Union:

25I-NBOMe , a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen; AH-7921 , a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as ‘doxylam’; MDPV , a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone and; methoxetamine , an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP) which has dissociative properties.

The implementing Decision implements Decision 2005/387/JHA that confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.

A risk assessment report on the four new psychoactive substances was drawn up in accordance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The report pointed out that further research would be needed to determine the health and social risks that these substances pose.

As a result of the health risks that they pose, as documented by their detection in several reported fatalities, of the fact that users may unknowingly consume them and of the lack of medical value or use of the substance, the four substances should be subjected to control measures across the Union.

Decision 2014/688/EU is replaced, without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws.

The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision, which implements Decision 2005/387/JHA, and is not bound by it or subject to its application.

ENTRY INTO FORCE: 21.10.2015.

Documents
Decision 2015/1875
OJ L 275 20.10.2015, p. 0038
2015/10/08
   EP/CSL - Act adopted by Council after consultation of Parliament
2015/10/08
   EP - End of procedure in Parliament
2015/10/06
   EP - Results of vote in Parliament
Documents
Results of vote in Parliament
2015/10/06
   EP - Decision by Parliament
Details

The European Parliament adopted by 651 votes to 6, with 33 abstentions, a legislative resolution on the draft Council implementing decision on subjecting 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloroN-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures.

In line with the Committee on Civil Liberties, Justice and Home Affairs, the European Parliament approved the Council draft aiming to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures.

Documents
T8-0328/2015
2015/09/28
   EP - Committee report tabled for plenary, 1st reading/single reading
Details

The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Teresa JIMÉNEZ-BECERRIL BARRIO (EPP, ES) on the draft Council implementing decision on subjecting 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloroN-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures.

The committee approved the Council draft which seeks to invite the Member States to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures.

In compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances. The risk assessment report was subsequently submitted to the Commission and to the Council on 23 April 2014.

Documents
A8-0264/2015
2015/09/22
   EP - Vote in committee
2015/09/03
   EP - JIMÉNEZ-BECERRIL BARRIO Teresa (PPE) appointed as rapporteur in LIBE
2015/09/01
   EP - Committee draft report
Documents
PE564.981
2015/07/09
   EP - Committee referral announced in Parliament
2015/06/30
   EC - Legislative proposal published
Details

PURPOSE: to subject 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures.

PROPOSED ACT: Implementing Council Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances 25I-NBOMe, AH-7921, MDPV and methoxetamine . The risk assessment reports were submitted to the Commission and to the Council on 23 April 2014.

(1) 25I-NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by virtue of Council Decision 2003/847/JHA. Twenty-two Member States and Norway have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 25I-NBOMe. There have been four deaths associated with 25I-NBOMe registered in three Member States. Severe toxicity associated with its use has been reported in four Member States, which notified 32 non-fatal intoxications. 25I-NBOMe is openly marketed and sold on the internet as a 'research chemical' and information obtained from seizures, collected samples, user websites and internet retailers suggests that it is being sold as a drug in its own right and also marketed as a 'legal' replacement for LSD. Six Member States control 25I-NBOMe under national legislation and seven Member States use other legislative measures to control it.

(2) AH-7921 is a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as 'doxylam'. It can be easily confused with 'doxylamine', an antihistaminic medicine with sedative-hypnotic properties, which could lead to unintentional overdoses. Based on user reports, the effects of AH-7921 appear to resemble those of classical opioids. Some of the users report self-medicating with this new drug to relieve pain.

15 fatalities were recorded in three Member States between December 2012 and September 2013 where AH-7921, alone or in combination with other substances, was detected in post-mortem samples. One Member State reported six non-fatal intoxications associated with AH-7921. One Member State controls AH-7921 under national legislation and five Member States use other legislative measures to control it.

(3) MDPV is a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone, which are both subject to control under the 1971 United Nations Convention on Psychotropic Substances. The psychopharmacological profile observed for MDPV is similar to that for cocaine and methamphetamine, albeit more potent and longer lasting. Acute toxicity can provoke adverse effects on humans.

MDPV has been present on the Union drug market since November 2008 and 27 Member States, Norway and Turkey have reported multi-kilogram seizures of the substance. MDPV is being sold as a substance in its own right, but it has also been detected in combination with other substances. It is widely available from internet suppliers and retailers, 'head shops' and street-level dealers.

108 fatalities were registered in eight Member States and Norway between September 2009 and August 2013, where MDPV has been detected in post-mortem biological samples or implicated in the cause of death. A total of 525 non-fatal intoxications associated with MDPV have been reported by eight Member States.

21 Member States control MDPV under national legislation and four Member States use other legislative measures to control it.

(4) Methoxetamine is an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP). Self-reported experiences from user websites suggest adverse effects similar to ketamine intoxication.

Twenty-three Member States, Turkey and Norway have reported that they reported detection of methoxetamine, since November 2010. Information suggests that it is sold and used as a substance in its own right, and that it is also sold as a 'legal' replacement for ketamine by internet retailers.

Twenty deaths associated with methoxetamine have been reported by six Member States that detected the substance in post-mortem samples. Used alone or in combination with other substances, methoxetamine was detected in 20 non-fatal intoxications reported by five Member States. Nine Member States control methoxetamine under national legislation and nine other Member States use other legislative measures to control it.

The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by methoxetamine. However, the available evidence and information provides sufficient grounds for subjecting methoxetamine to control measures across the Union. As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, methoxetamine should be subjected to control measures across the Union.

CONTENT: this proposal aims to invite the Member States to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures across the Union .

Decision 2014/688/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws.

The United Kingdom shall not take part in the adoption of this Decision and is not bound by it or subject to its application.

Documents
10011/2015
2014/06/16
   EC - Initial legislative proposal
Documents
EUR-Lex
COM(2014)0362
2014/06/16
   EC - Initial legislative proposal published
Documents
EUR-Lex
COM(2014)0362

Documents

Activities

Votes

A8-0264/2015 - Teresa Jiménez-Becerril Barrio - Vote unique #

2015/10/06 Outcome: +: 651, 0: 33, -: 6
DE FR IT ES PL RO GB HU CZ BE SE EL PT NL BG AT FI SK HR DK LT LV IE SI CY MT EE LU
Total
89
72
70
49
46
30
58
20
21
19
19
19
18
25
16
16
12
12
11
11
10
8
9
8
6
6
5
4
icon: PPE PPE
203

Germany PPE

30

France PPE

19

Italy PPE

15

Spain PPE

14

Poland PPE

23

Romania PPE

13

Hungary PPE

11

Czechia PPE

7

Belgium PPE

3

Sweden PPE

4

Greece PPE

5

Portugal PPE

6

Netherlands PPE

5

Bulgaria PPE

7

Austria PPE

4

Finland PPE

3

Slovakia PPE

5

Croatia PPE

5

Denmark PPE

For (1)

Bendt BENDTSEN
1

Lithuania PPE

2

Latvia PPE

4

Ireland PPE

4

Slovenia PPE

5

Cyprus PPE

2

Malta PPE

3

Estonia PPE

For (1)

Tunne KELAM
1

Luxembourg PPE

2
icon: S&D S&D
180

Germany S&D

26

France S&D

13

Italy S&D

28

Spain S&D

13

Poland S&D

4

Romania S&D

14

United Kingdom S&D

20

Hungary S&D

4

Czechia S&D

4

Belgium S&D

4

Sweden S&D

5

Greece S&D

3

Portugal S&D

8

Netherlands S&D

2

Bulgaria S&D

4

Austria S&D

5

Finland S&D

2

Slovakia S&D

4

Croatia S&D

2

Denmark S&D

3

Lithuania S&D

2

Latvia S&D

1

Ireland S&D

For (1)

Nessa CHILDERS
1

Slovenia S&D

For (1)

Tanja FAJON
1

Cyprus S&D

2

Malta S&D

3

Estonia S&D

For (1)

Marju LAURISTIN
1

Luxembourg S&D

For (1)

Mady DELVAUX
1
icon: ALDE ALDE
65

Germany ALDE

4

France ALDE

7

Spain ALDE

8

Romania ALDE

2

United Kingdom ALDE

1

Czechia ALDE

4

Belgium ALDE

6

Sweden ALDE

3

Portugal ALDE

2

Netherlands ALDE

7

Bulgaria ALDE

4

Austria ALDE

For (1)

Angelika MLINAR
1

Finland ALDE

4

Croatia ALDE

2

Denmark ALDE

2

Lithuania ALDE

3

Latvia ALDE

1

Ireland ALDE

For (1)

Marian HARKIN
1

Slovenia ALDE

For (1)

Ivo VAJGL
1

Estonia ALDE

2
icon: GUE/NGL GUE/NGL
47

Germany GUE/NGL

8

France GUE/NGL

4

Italy GUE/NGL

3

Spain GUE/NGL

10

United Kingdom GUE/NGL

1

Czechia GUE/NGL

3

Sweden GUE/NGL

For (1)

Malin BJÖRK
1

Greece GUE/NGL

5

Portugal GUE/NGL

2

Netherlands GUE/NGL

3

Finland GUE/NGL

For (1)

Merja KYLLÖNEN
1

Denmark GUE/NGL

For (1)

Rina Ronja KARI
1

Ireland GUE/NGL

Abstain (1)

Luke Ming FLANAGAN
3

Cyprus GUE/NGL

2
icon: Verts/ALE Verts/ALE
46

Germany Verts/ALE

11

France Verts/ALE

6

Spain Verts/ALE

4

United Kingdom Verts/ALE

5

Hungary Verts/ALE

2

Belgium Verts/ALE

2

Sweden Verts/ALE

4

Netherlands Verts/ALE

2

Austria Verts/ALE

2

Finland Verts/ALE

For (1)

Heidi HAUTALA
1

Croatia Verts/ALE

For (1)

Davor ŠKRLEC
1

Denmark Verts/ALE

For (1)

Margrete AUKEN
1

Lithuania Verts/ALE

For (1)

Bronis ROPĖ
1

Latvia Verts/ALE

1

Slovenia Verts/ALE

For (1)

Igor ŠOLTES
1

Estonia Verts/ALE

For (1)

Indrek TARAND
1

Luxembourg Verts/ALE

For (1)

Claude TURMES
1
icon: ECR ECR
55

Germany ECR

8

Italy ECR

2

Poland ECR

17

United Kingdom ECR

9

Czechia ECR

2

Belgium ECR

3

Greece ECR

For (1)

Notis MARIAS
1

Netherlands ECR

2

Bulgaria ECR

1

Finland ECR

For (1)

Jussi HALLA-AHO
1

Slovakia ECR

3

Croatia ECR

For (1)

Ruža TOMAŠIĆ
1

Denmark ECR

3

Lithuania ECR

1

Latvia ECR

For (1)

Roberts ZĪLE
1
icon: ENF ENF
38

France ENF

21

Italy ENF

5

Poland ENF

For (1)

Michał MARUSIK
1

Romania ENF

1

United Kingdom ENF

Abstain (1)

Janice ATKINSON
1

Belgium ENF

For (1)

Gerolf ANNEMANS
1

Netherlands ENF

4

Austria ENF

4
icon: EFDD EFDD
43

France EFDD

1

Italy EFDD

17

Poland EFDD

1

United Kingdom EFDD

20

Czechia EFDD

Against (1)

Petr MACH
1

Sweden EFDD

2

Lithuania EFDD

For (1)

Rolandas PAKSAS
1
icon: NI NI
12

Germany NI

For (1)

Udo VOIGT

Against (1)

Martin SONNEBORN
2

France NI

For (1)

Bruno GOLLNISCH
1

United Kingdom NI

For (1)

Diane DODDS
1

Hungary NI

3

Greece NI

5

History

(these mark the time of scraping, not the official date of the change)

2021-12-18Show (9) Changes | Timetravel
docs/1/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE564.981
New
https://www.europarl.europa.eu/doceo/document/LIBE-PR-564981_EN.html
events/1/docs/0/url
Old
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
events/2/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament
events/3/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee
events/4/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-8-2015-0264_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-8-2015-0264_EN.html
events/6
date
2015-10-06T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-8-2015-0328_EN.html title: T8-0328/2015
summary
events/6
date
2015-10-06T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-8-2015-0328_EN.html title: T8-0328/2015
summary
procedure/Modified legal basis
Rules of Procedure EP 159
procedure/Other legal basis
Rules of Procedure EP 159
2020-01-19Show (4) Changes | Timetravel
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
rapporteur
name: JIMÉNEZ-BECERRIL BARRIO Teresa date: 2015-09-03T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
date
2015-09-03T00:00:00
rapporteur
name: JIMÉNEZ-BECERRIL BARRIO Teresa group: European People's Party (Christian Democrats) abbr: PPE
events/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0264&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-8-2015-0264_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0328
New
http://www.europarl.europa.eu/doceo/document/TA-8-2015-0328_EN.html
2019-07-06Show (17) Changes | Timetravel
activities
  • date: 2014-06-16T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0362 title: COM(2014)0362 type: Initial legislative proposal published celexid: CELEX:52014PC0362:EN body: EC commission: DG: url: http://ec.europa.eu/justice/ title: Justice Commissioner: JOUROVÁ Věra type: Initial legislative proposal published
  • date: 2015-06-30T00:00:00 docs: url: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT type: Legislative proposal published title: 10011/2015 body: EC commission: DG: url: http://ec.europa.eu/justice/ title: Justice Commissioner: JOUROVÁ Věra type: Legislative proposal published
  • date: 2015-07-09T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: True committee: LIBE date: 2015-09-03T00:00:00 committee_full: Civil Liberties, Justice and Home Affairs rapporteur: group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa
  • date: 2015-09-22T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: True committee: LIBE date: 2015-09-03T00:00:00 committee_full: Civil Liberties, Justice and Home Affairs rapporteur: group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa
  • body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0264&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A8-0264/2015 type: Committee report tabled for plenary, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: True committee: LIBE date: 2015-09-03T00:00:00 committee_full: Civil Liberties, Justice and Home Affairs rapporteur: group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa date: 2015-09-28T00:00:00
  • date: 2015-10-06T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=26165&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0328 type: Decision by Parliament, 1st reading/single reading title: T8-0328/2015 body: EP type: Results of vote in Parliament
  • date: 2015-10-08T00:00:00 body: EP/CSL type: Act adopted by Council after consultation of Parliament
  • date: 2015-10-20T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1875 title: Decision 2015/1875 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2015:275:TOC title: OJ L 275 20.10.2015, p. 0038 type: Final act published in Official Journal
commission
  • body: EC dg: Justice and Consumers commissioner: JOUROVÁ Věra
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
date
2015-09-03T00:00:00
rapporteur
name: JIMÉNEZ-BECERRIL BARRIO Teresa group: European People's Party (Christian Democrats) abbr: PPE
committees/0
body
EP
responsible
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
opinion
False
committees/1
body
EP
responsible
True
committee
LIBE
date
2015-09-03T00:00:00
committee_full
Civil Liberties, Justice and Home Affairs
rapporteur
group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa
docs
  • date: 2014-06-16T00:00:00 docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0362 title: EUR-Lex title: COM(2014)0362 type: Initial legislative proposal body: EC
  • date: 2015-09-01T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE564.981 title: PE564.981 type: Committee draft report body: EP
events
  • date: 2014-06-16T00:00:00 type: Initial legislative proposal published body: EC docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0362 title: EUR-Lex title: COM(2014)0362
  • date: 2015-06-30T00:00:00 type: Legislative proposal published body: EC docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT title: 10011/2015 summary: PURPOSE: to subject 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures. PROPOSED ACT: Implementing Council Decision. ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion. BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances 25I-NBOMe, AH-7921, MDPV and methoxetamine . The risk assessment reports were submitted to the Commission and to the Council on 23 April 2014. (1) 25I-NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by virtue of Council Decision 2003/847/JHA. Twenty-two Member States and Norway have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 25I-NBOMe. There have been four deaths associated with 25I-NBOMe registered in three Member States. Severe toxicity associated with its use has been reported in four Member States, which notified 32 non-fatal intoxications. 25I-NBOMe is openly marketed and sold on the internet as a 'research chemical' and information obtained from seizures, collected samples, user websites and internet retailers suggests that it is being sold as a drug in its own right and also marketed as a 'legal' replacement for LSD. Six Member States control 25I-NBOMe under national legislation and seven Member States use other legislative measures to control it. (2) AH-7921 is a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as 'doxylam'. It can be easily confused with 'doxylamine', an antihistaminic medicine with sedative-hypnotic properties, which could lead to unintentional overdoses. Based on user reports, the effects of AH-7921 appear to resemble those of classical opioids. Some of the users report self-medicating with this new drug to relieve pain. 15 fatalities were recorded in three Member States between December 2012 and September 2013 where AH-7921, alone or in combination with other substances, was detected in post-mortem samples. One Member State reported six non-fatal intoxications associated with AH-7921. One Member State controls AH-7921 under national legislation and five Member States use other legislative measures to control it. (3) MDPV is a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone, which are both subject to control under the 1971 United Nations Convention on Psychotropic Substances. The psychopharmacological profile observed for MDPV is similar to that for cocaine and methamphetamine, albeit more potent and longer lasting. Acute toxicity can provoke adverse effects on humans. MDPV has been present on the Union drug market since November 2008 and 27 Member States, Norway and Turkey have reported multi-kilogram seizures of the substance. MDPV is being sold as a substance in its own right, but it has also been detected in combination with other substances. It is widely available from internet suppliers and retailers, 'head shops' and street-level dealers. 108 fatalities were registered in eight Member States and Norway between September 2009 and August 2013, where MDPV has been detected in post-mortem biological samples or implicated in the cause of death. A total of 525 non-fatal intoxications associated with MDPV have been reported by eight Member States. 21 Member States control MDPV under national legislation and four Member States use other legislative measures to control it. (4) Methoxetamine is an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP). Self-reported experiences from user websites suggest adverse effects similar to ketamine intoxication. Twenty-three Member States, Turkey and Norway have reported that they reported detection of methoxetamine, since November 2010. Information suggests that it is sold and used as a substance in its own right, and that it is also sold as a 'legal' replacement for ketamine by internet retailers. Twenty deaths associated with methoxetamine have been reported by six Member States that detected the substance in post-mortem samples. Used alone or in combination with other substances, methoxetamine was detected in 20 non-fatal intoxications reported by five Member States. Nine Member States control methoxetamine under national legislation and nine other Member States use other legislative measures to control it. The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by methoxetamine. However, the available evidence and information provides sufficient grounds for subjecting methoxetamine to control measures across the Union. As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, methoxetamine should be subjected to control measures across the Union. CONTENT: this proposal aims to invite the Member States to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures across the Union . Decision 2014/688/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws. The United Kingdom shall not take part in the adoption of this Decision and is not bound by it or subject to its application.
  • date: 2015-07-09T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2015-09-22T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2015-09-28T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0264&language=EN title: A8-0264/2015 summary: The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Teresa JIMÉNEZ-BECERRIL BARRIO (EPP, ES) on the draft Council implementing decision on subjecting 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloroN-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures. The committee approved the Council draft which seeks to invite the Member States to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures. In compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances. The risk assessment report was subsequently submitted to the Commission and to the Council on 23 April 2014.
  • date: 2015-10-06T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=26165&l=en title: Results of vote in Parliament
  • date: 2015-10-06T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0328 title: T8-0328/2015 summary: The European Parliament adopted by 651 votes to 6, with 33 abstentions, a legislative resolution on the draft Council implementing decision on subjecting 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloroN-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures. In line with the Committee on Civil Liberties, Justice and Home Affairs, the European Parliament approved the Council draft aiming to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures.
  • date: 2015-10-08T00:00:00 type: Act adopted by Council after consultation of Parliament body: EP/CSL
  • date: 2015-10-08T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2015-10-20T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to apply control measures to new psychoactive substances. NON-LEGISLATIVE ACT: Council Implementing Decision (EU) 2015/1875 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures. CONTENT: the Council adopted an implementing decision on subjecting the new psychoactive substances to control measures across the European Union: 25I-NBOMe , a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen; AH-7921 , a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as ‘doxylam’; MDPV , a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone and; methoxetamine , an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP) which has dissociative properties. The implementing Decision implements Decision 2005/387/JHA that confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union. A risk assessment report on the four new psychoactive substances was drawn up in accordance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The report pointed out that further research would be needed to determine the health and social risks that these substances pose. As a result of the health risks that they pose, as documented by their detection in several reported fatalities, of the fact that users may unknowingly consume them and of the lack of medical value or use of the substance, the four substances should be subjected to control measures across the Union. Decision 2014/688/EU is replaced, without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws. The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision, which implements Decision 2005/387/JHA, and is not bound by it or subject to its application. ENTRY INTO FORCE: 21.10.2015. docs: title: Decision 2015/1875 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1875 title: OJ L 275 20.10.2015, p. 0038 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2015:275:TOC
links
other
  • body: EC dg: url: http://ec.europa.eu/justice/ title: Justice commissioner: JOUROVÁ Věra
procedure/Modified legal basis
Old
Rules of Procedure of the European Parliament EP 150
New
Rules of Procedure EP 159
procedure/dossier_of_the_committee
Old
LIBE/8/03857
New
  • LIBE/8/03857
procedure/final/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1875
New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1875
procedure/instrument
Old
Decision
New
  • Decision
  • See also Decision 2005/387/JHA 2003/0215(CNS)
procedure/subject
Old
  • 7.30.30.04 Action to combat drugs and drug-trafficking
New
7.30.30.04
Action to combat drugs and drug-trafficking
procedure/summary
  • See also Decision 2005/387/JHA
procedure/title
Old
Implementing decision on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures
New
Subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures
2016-07-06Show (2) Changes | Timetravel
activities/6
date
2015-10-08T00:00:00
body
EP/CSL
type
Act adopted by Council after consultation of Parliament
procedure/stage_reached
Old
Awaiting final decision
New
Procedure completed
2016-07-05Show (2) Changes | Timetravel
activities/6
date
2015-10-20T00:00:00
docs
type
Final act published in Official Journal
procedure/final
url
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1875
title
Decision 2015/1875
2016-07-01Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-25Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-06-24Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-22Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-06-19Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-17Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-06-16Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-14Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-06-09Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-07Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-06-05Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-06-02Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-21Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-18Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-17Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-15Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-14Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-12Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-10Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-09Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-08Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-04Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-05-02Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-05-01Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-30Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-29Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-26Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-25Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-24Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-21Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-16Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-12Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-11Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-10Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-09Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-08Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-07Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-04-04Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-04-02Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-31Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-24Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-23Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-18Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-15Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-12Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-10Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-09Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-05Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-04Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-03-03Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
New
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
2016-03-02Show (1) Changes | Timetravel
activities/1/docs/0/url
Old
http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
New
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2015[%DESCRIPTOR]10011:EN:NOT
2016-02-11Show (2) Changes | Timetravel
activities/5/docs/0
url
http://www.europarl.europa.eu/oeil/popups/sda.do?id=26165&l=en
type
Results of vote in Parliament
title
Results of vote in Parliament
activities/5/type
Old
Decision by Parliament, 1st reading/single reading
New
Results of vote in Parliament
2015-11-04Show (1) Changes | Timetravel
activities/0/docs/0/celexid
CELEX:52014PC0362:EN
2015-10-21Show (12) Changes | Timetravel
activities/0/commission/0
DG
Commissioner
JOUROVÁ Věra
activities/1/commission/0
DG
Commissioner
JOUROVÁ Věra
activities/2/committees/1/date
2015-09-03T00:00:00
activities/2/committees/1/rapporteur
  • group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa
activities/3
date
2015-09-22T00:00:00
body
EP
type
Vote in committee, 1st reading/single reading
committees
activities/4
body
EP
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0264&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A8-0264/2015
type
Committee report tabled for plenary, 1st reading/single reading
committees
date
2015-09-28T00:00:00
activities/5
date
2015-10-06T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0328 type: Decision by Parliament, 1st reading/single reading title: T8-0328/2015
body
EP
type
Decision by Parliament, 1st reading/single reading
committees/1/date
2015-09-03T00:00:00
committees/1/rapporteur
  • group: EPP name: JIMÉNEZ-BECERRIL BARRIO Teresa
other/0
body
EC
dg
commissioner
JOUROVÁ Věra
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 150
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting final decision
2015-07-31Show (1) Changes | Timetravel
activities/1/docs/0/text

  • PURPOSE: to subject 4-iodo-2,5dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures.

    PROPOSED ACT: Implementing Council Decision.

    ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

    BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substances 25I-NBOMe, AH-7921, MDPV and methoxetamine. The risk assessment reports were submitted to the Commission and to the Council on 23 April 2014.

    (1) 25I-NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical serotonergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by virtue of Council Decision 2003/847/JHA. Twenty-two Member States and Norway have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 25I-NBOMe. There have been four deaths associated with 25I-NBOMe registered in three Member States. Severe toxicity associated with its use has been reported in four Member States, which notified 32 non-fatal intoxications. 25I-NBOMe is openly marketed and sold on the internet as a 'research chemical' and information obtained from seizures, collected samples, user websites and internet retailers suggests that it is being sold as a drug in its own right and also marketed as a 'legal' replacement for LSD. Six Member States control 25I-NBOMe under national legislation and seven Member States use other legislative measures to control it.

    (2) AH-7921 is a structurally atypical synthetic opioid analgesic commonly known by internet suppliers, user websites and media as 'doxylam'. It can be easily confused with 'doxylamine', an antihistaminic medicine with sedative-hypnotic properties, which could lead to unintentional overdoses. Based on user reports, the effects of AH-7921 appear to resemble those of classical opioids. Some of the users report self-medicating with this new drug to relieve pain.

    15 fatalities were recorded in three Member States between December 2012 and September 2013 where AH-7921, alone or in combination with other substances, was detected in post-mortem samples. One Member State reported six non-fatal intoxications associated with AH-7921. One Member State controls AH-7921 under national legislation and five Member States use other legislative measures to control it.

    (3) MDPV is a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone, which are both subject to control under the 1971 United Nations Convention on Psychotropic Substances. The psychopharmacological profile observed for MDPV is similar to that for cocaine and methamphetamine, albeit more potent and longer lasting. Acute toxicity can provoke adverse effects on humans.

    MDPV has been present on the Union drug market since November 2008 and 27 Member States, Norway and Turkey have reported multi-kilogram seizures of the substance. MDPV is being sold as a substance in its own right, but it has also been detected in combination with other substances. It is widely available from internet suppliers and retailers, 'head shops' and street-level dealers.

    108 fatalities were registered in eight Member States and Norway between September 2009 and August 2013, where MDPV has been detected in post-mortem biological samples or implicated in the cause of death. A total of 525 non-fatal intoxications associated with MDPV have been reported by eight Member States.

    21 Member States control MDPV under national legislation and four Member States use other legislative measures to control it.

    (4) Methoxetamine is an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP). Self-reported experiences from user websites suggest adverse effects similar to ketamine intoxication.

    Twenty-three Member States, Turkey and Norway have reported that they reported detection of methoxetamine, since November 2010. Information suggests that it is sold and used as a substance in its own right, and that it is also sold as a 'legal' replacement for ketamine by internet retailers.

    Twenty deaths associated with methoxetamine have been reported by six Member States that detected the substance in post-mortem samples. Used alone or in combination with other substances, methoxetamine was detected in 20 non-fatal intoxications reported by five Member States. Nine Member States control methoxetamine under national legislation and nine other Member States use other legislative measures to control it.

    The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by methoxetamine. However, the available evidence and information provides sufficient grounds for subjecting methoxetamine to control measures across the Union. As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, methoxetamine should be subjected to control measures across the Union.

    CONTENT: this proposal aims to invite the Member States to subject 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures across the Union.

    Decision 2014/688/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws.

    The United Kingdom shall not take part in the adoption of this Decision and is not bound by it or subject to its application.
2015-07-15Show (5) Changes
activities
  • date: 2014-06-16T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0362 type: Initial legislative proposal published title: COM(2014)0362 body: EC commission: type: Initial legislative proposal published
  • date: 2015-06-30T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=10011%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Legislative proposal published title: 10011/2015 body: EC commission: type: Legislative proposal published
  • date: 2015-07-09T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: True committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
committees
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: True committee_full: Civil Liberties, Justice and Home Affairs committee: LIBE
links
other
    procedure
    dossier_of_the_committee
    LIBE/8/03857
    reference
    2014/0183(NLE)
    instrument
    Decision
    legal_basis
    Treaty on the European Union (after Amsterdam) M 039-p1
    stage_reached
    Awaiting committee decision
    summary
    See also Decision 2005/387/JHA
    subtype
    Consultation of Parliament
    title
    Implementing decision on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures
    type
    NLE - Non-legislative enactments
    subject
    7.30.30.04 Action to combat drugs and drug-trafficking
    @parltrack
    @parltrack@eupolicy.social
    [javascript protected email address]
    code AGPLv3.0+
    data ODBLv1.0
    site content CC-By-Sa-3.0

    ParlTrack - 2011-2024

    © European Union, 2011 – Source: European Parliament
    Hosted by AS250.net Foundation